|
|
Article: MDS Nordion to manufacture Molecular Insight's lead molecular imaging pharmaceutical.
- Article from:
- PR Newswire
- Article date:
- June 17, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New iodine-123 based cardiac imaging pharmaceutical, BMIPP, in advanced clinical development
MDS Nordion and Molecular Insight Pharmaceuticals have signed a development and contract manufacturing agreement to produce BMIPP. BMIPP is Molecular Insight's lead molecular imaging pharmaceutical. BMIPP is currently in a multi-center Phase IIb clinical trial in the United States, for the detection of cardiac ischemia in the emergency department setting. BMIPP is labelled with MDS Nordion's high- purity iodine- 123 to provide superior imaging quality. The new cardiac imaging pharmaceutical will be manufactured at MDS Nordion's cyclotron facility in Vancouver, Canada.
...